Search

Your search keyword '"UEMURA, Motohide"' showing total 959 results
Start Over Author "UEMURA, Motohide"
959 results on '"UEMURA, Motohide"'

1. Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model

Author

Yaginuma, Kei, Takahashi, Kazuhiro, Hoshi, Seiji, Joho, Taiki, Shimoyama, Saki, Hasegawa, Naoko, Hasegawa, Koki, Zhao, Songji, Ukon, Naoyuki, Makabe, Syunta, Meguro, Satoru, Onagi, Akifumi, Matsuoka, Kanako, Ogawa, Soichiro, Uemura, Motohide, Yamashita, Tomoki, Suzuki, Hiroyuki, Uehara, Tomoya, and Kojima, Yoshiyuki

Published
2025
Full Text
View/download PDF

2. GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment

Author

Yamamichi, Gaku, Kato, Taigo, Arakawa, Noriaki, Ino, Yoko, Ujike, Takeshi, Nakano, Kosuke, Koh, Yoko, Motoyama, Yuichi, Outani, Hidetatsu, Myoba, Shohei, Ishizuya, Yu, Yamamoto, Yoshiyuki, Hatano, Koji, Kawashima, Atsunari, Fukuhara, Shinichiro, Uemura, Hiroji, Okada, Seiji, Morii, Eiichi, Nonomura, Norio, and Uemura, Motohide

Published
2024
Full Text
View/download PDF

6. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory

Author

Kidani, Yujiro, Nogami, Wataru, Yasumizu, Yoshiaki, Kawashima, Atsunari, Tanaka, Atsushi, Sonoda, Yudai, Tona, Yumi, Nashiki, Kunitaka, Matsumoto, Reimi, Hagiwara, Masaki, Osaki, Motonao, Dohi, Keiji, Kanazawa, Takayuki, Ueyama, Azumi, Yoshikawa, Mai, Yoshida, Tetsuya, Matsumoto, Mitsunobu, Hojo, Kanji, Shinonome, Satomi, Yoshida, Hiroshi, Hirata, Michinari, Haruna, Miya, Nakamura, Yamami, Motooka, Daisuke, Okuzaki, Daisuke, Sugiyama, Yasuko, Kinoshita, Makoto, Okuno, Tatsusada, Kato, Taigo, Hatano, Koji, Uemura, Motohide, Imamura, Ryoichi, Yokoi, Kazunori, Tanemura, Atsushi, Shintani, Yasushi, Kimura, Tadashi, Nonomura, Norio, Wada, Hisashi, Mori, Masaki, Doki, Yuichiro, Ohkura, Naganari, and Sakaguchi, Shimon

Published
2022

7. Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients

Author

Jingushi, Kentaro, Kawashima, Atsunari, Saito, Takuro, Kanazawa, Takayuki, Motooka, Daisuke, Kimura, Tomonori, Mita, Masashi, Yamamoto, Akinaru, Uemura, Toshihiro, Yamamichi, Gaku, Okada, Koichi, Tomiyama, Eisuke, Koh, Yoko, Matsushita, Makoto, Kato, Taigo, Hatano, Koji, Uemura, Motohide, Tsujikawa, Kazutake, Wada, Hisashi, and Nonomura, Norio

Published
2022
Full Text
View/download PDF

8. EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer

Author

Tomiyama, Eisuke, Fujita, Kazutoshi, Matsuzaki, Kyosuke, Narumi, Ryohei, Yamamoto, Akinaru, Uemura, Toshihiro, Yamamichi, Gaku, Koh, Yoko, Matsushita, Makoto, Hayashi, Yujiro, Hashimoto, Mamoru, Banno, Eri, Kato, Taigo, Hatano, Koji, Kawashima, Atsunari, Uemura, Motohide, Ukekawa, Ryo, Takao, Tetsuya, Takada, Shingo, Uemura, Hirotsugu, Adachi, Jun, Tomonaga, Takeshi, and Nonomura, Norio

Published
2022
Full Text
View/download PDF

9. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study

Author

Kato, Taigo, Fujita, Kazutoshi, Minami, Takafumi, Nagahara, Akira, Hyashi, Yujiro, Nakata, Wataru, Matsuzaki, Kyosuke, Nakano, Kosuke, Hatano, Koji, Kawashima, Atsunari, Imamura, Ryoichi, Takada, Shingo, Nishimura, Kensaku, Tsujihata, Masao, Takao, Tetsuya, Nakai, Yasutomo, Nakayama, Masashi, Nishimura, Kazuo, Uemura, Motohide, Uemura, Hirotsugu, and Nonomura, Norio

Published
2022
Full Text
View/download PDF

10. Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG

Author

Inoue, Takamitsu, Miyake, Makito, Nishimura, Nobutaka, Onozawa, Mizuki, Kashima, Soki, Numakura, Kazuyuki, Narita, Shintaro, Iida, Kota, Uemura, Motohide, Matsushita, Yuto, Inokuchi, Junichi, Matsui, Yoshiyuki, Taoka, Rikiya, Kojima, Takahiro, Kobayashi, Takashi, Nishiyama, Naotaka, Kitamura, Hiroshi, Nishiyama, Hiroyuki, Fujimoto, Kiyohide, and Habuchi, Tomonori

Published
2022
Full Text
View/download PDF

11. Longitudinal changes in factors affecting postoperative patient satisfaction after robot-assisted radical prostatectomy: an assessment using a patient-reported questionnaire.

Author

Ogawa, Soichiro, Yaginuma, Kei, Harigane, Yuki, Makabe, Shunta, Imai, Hitomi, Meguro, Satoru, Tanji, Ryo, Onagi, Akifumi, Honda-Takinami, Ruriko, Matsuoka, Kanako, Hoshi, Seiji, Hata, Junya, Sato, Yuichi, Akaihata, Hidenori, Kataoka, Masao, Uemura, Motohide, and Kojima, Yoshiyuki

Abstract

Background: Long-term survival can be achieved in patients with localized prostate cancer (PCa). Therefore, maintenance of postoperative quality of life (QOL) and treatment satisfaction are important. Although longitudinal changes in disease-specific QOL are reported, there are few studies investigating which factors longitudinally affect treatment satisfaction in patients who undergo robot-assisted radical prostatectomy (RARP). Therefore, we examined the factors associated with treatment satisfaction over the first 12 months postoperatively based on an assessment using a patient-reported questionnaire. Methods: Of the 612 consecutive patients who underwent RARP, 408 patients were enrolled in this study and divided into a satisfied group and a non-satisfied group at every evaluation timepoint. Multivariate logistic regression analysis was conducted to clarify factors affecting the postoperative treatment satisfaction between the two groups. Results: Multivariate logistic regression analysis revealed that factors relating to treatment satisfaction had longitudinally changed. Urinary bother (UB) (odds ratio (OR) = 1.023; p = 0.008), and sexual function (SF) (OR = 0.941; p = 0.004) were the significant factors associated with treatment satisfaction at 1 month postoperatively; UB (OR = 1.040; p = 0.001) and sexual bother (SB) (OR = 1.019; p < 0.001) at 3 months; urinary function (UF) (OR = 1.027; p = 0.008), UB (OR = 1.035; p = 0.011), SB (OR = 1.013; p = 0.009), and hormonal bother (HB) (OR = 1.065; p = 0.023) at 6 months; UF (OR = 1.026; p = 0.008), UB (OR = 1.030; p = 0.029), and SB (OR = 1.014; p = 0.004) at 9 months; UF (OR = 1.024; p = 0.002) at 12 months. Conclusions: Treatment satisfaction in patients who underwent RARP changed over time. Our results suggest that giving sufficient information before treatment choice is both important and useful for patients' decision-making, leading to improved patient QOL. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

12. Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model.

Author

Yaginuma, Kei, Takahashi, Kazuhiro, Hoshi, Seiji, Joho, Taiki, Shimoyama, Saki, Hasegawa, Naoko, Hasegawa, Koki, Zhao, Songji, Ukon, Naoyuki, Makabe, Syunta, Meguro, Satoru, Onagi, Akifumi, Matsuoka, Kanako, Ogawa, Soichiro, Uemura, Motohide, Yamashita, Tomoki, Suzuki, Hiroyuki, Uehara, Tomoya, and Kojima, Yoshiyuki

Subjects
PROSTATE-specific membrane antigen, CASTRATION-resistant prostate cancer, MEDICAL sciences, KIDNEY tubules, STRUCTURAL stability
Abstract

Purpose: Prostate-specific membrane antigen (PSMA)-targeted alpha therapy is considered a promising alternative treatment for metastatic castration-resistant prostate cancer (mCRPC). Though astatine-211 (211At) is potentially useful alpha-emitter producible by cyclotrons, its clinical application has been limited by instability and a tendency to deastatination in vivo. To overcome these challenges, we developed [211At]At-NpG-PSMA, a novel PSMA ligand with a neopentyl-glycol structure that enhances in vivo stability against deastatination. This study aimed to evaluate the stability, anti-tumour effect, and safety of [211At]At-NpG-PSMA in mice. Methods: Xenograft models were prepared by subcutaneous transplantation of PSMA-positive PC-3 PIP cells into BALB/c nu/nu mice. [211At]At-NpG-PSMA was administered to assess biodistribution, and the anti-tumour effect was evaluated at doses of 0.32, 1.00 and 1.93 MBq in comparison with saline. Histopathological examinations were performed to evaluate damage to normal organs. Results: [211At]At-NpG-PSMA demonstrated high tumour uptake (42.0 ± 13.1%ID/g at 3 h) with minimal uptake in non-target tissues, including thyroid, stomach and salivary grands (0.28 ± 0.20%ID, 0.71 ± 0.12%ID/g and 0.88 ± 0.10%ID/g at 3 h, respectively). A dose-dependent anti-tumour effect was observed, with tumour volumes increasing by 796.0 ± 437.6% in the control versus 161.0 ± 213.4%, -76.4 ± 19.2% and − 59.5 ± 41.6% in the 0.32, 1.00 and 1.93 MBq groups, respectively, by day 15. Mild renal tubule regeneration was noted in the 1.00 MBq group. Conclusion: [211At]At-NpG-PSMA demonstrated significant stability in vivo and anti-tumour effects with minimal side effects, indicating its potential as a new therapeutic drug for PSMA-targeted alpha therapy in mCRPC. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

13. Proliferative mechanism of benign prostatic hyperplasia by NLRP3 inflammasome through the complement pathway.

Author

Hata, Junya, Matsuoka, Kanako, Harigane, Yuki, Yaginuma, Kei, Akaihata, Hidenori, Meguro, Satoru, Honda‐Takinami, Ruriko, Onagi, Akifumi, Sato, Yuichi, Ogawa, Soichiro, Uemura, Motohide, and Kojima, Yoshiyuki

Subjects
LABORATORY rats, BENIGN prostatic hyperplasia, COMPLEMENT (Immunology), WESTERN immunoblotting, NLRP3 protein
Abstract

Objectives: The expressions of complement component C5a and NLRP3 inflammasome and the antiproliferative effect of resveratrol in benign prostatic hyperplasia (BPH) model rat were analyzed to clarify the BPH proliferative mechanism. Methods: This study used the pathological stromal‐dominant BPH model rat by urogenital sinus implantation (UGS). Expression of C5a, NLRP3, Caspase‐1, IL‐1β, and IL‐18 using rat BPH tissues at 2, 3, and 8 weeks (n = 6, respectively) after UGS implantation were analyzed by qRT‐PCR, western blotting analysis, and immunohistochemical (IHC) analysis. Serum IL‐1β levels in BPH model and sham rats were measured by enzyme‐linked immunosorbent assay. Furthermore, resveratrol, as the NLRP3 pathway inhibitor, was administered to BPH model rat to assess the antiproliferative effect on the BPH proliferative process. The proliferative effect on prostate was evaluated by Ki‐67 protein expression. Results: The expression levels of C5a, NLRP3, Caspase‐1, IL‐1β, and IL‐18 in qRT‐PCR, western blotting, and IHC were significantly upregulated in BPH tissues compared to control prostate tissues and showed increases with time (all p < 0.05). Serum IL‐1β levels in BPH model rats had significantly increased compared to sham rats. On IHC, deposition of C5a, NLRP3, Caspase‐1, IL‐1β, and IL‐18 was abundant in stromal areas of BPH. The administration of resveratrol significantly decreased prostate weight and expressions of NLRP3, IL‐1β, IL‐18, and Ki‐67 (all p < 0.05). Conclusions: NLRP3 inflammasome activation by complement C5a produces IL‐1β and IL‐18 through Caspase‐1 during the BPH proliferative process. NLRP3 inflammasome have the possibilities to be a therapeutic target for BPH proliferation by inhibiting the NLRP3 inflammasome pathway. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. A Novel Gene Expression Scoring System Predicts Recurrence in Non‐Muscle‐Invasive Bladder Cancer Patients.

Author

Kayama, Emina, Uemura, Motohide, Onagi, Akifumi, Meguro, Satoru, Ogawa, Soichiro, Yaginuma, Kei, Matsuoka, Kanako, Hoshi, Seiji, Koguchi, Tomoyuki, Hata, Junya, Sato, Yuichi, Akaihata, Hidenori, Honma, Reiko, Watanabe, Shinya, and Kojima, Yoshiyuki

Subjects
*TRANSURETHRAL resection of bladder, *GENE expression, *GENE expression profiling, *CANCER patients, *UNIVARIATE analysis, *BLADDER cancer
Abstract

Background: Despite the high recurrence rate of non‐muscle‐invasive bladder cancer (NMIBC), there are limitations in accurately predicting recurrence after transurethral resection of bladder tumor (TURBT) based on clinicopathological factors alone. However, prediction of recurrence using biomolecular characteristics of bladder tumors has not been applied to clinical practice. The objective of this study was to establish a new gene expression scoring system for identifying patients at high risk of recurrence. Methods: NMIBC and normal bladder samples were subjected to microarray analysis to obtain gene expression profiles. We identified 6 genes that were specifically upregulated in bladder cancer and also in recurrent cases. All patients were randomly grouped into a discovery cohort (n = 59) and a validation cohort (n = 30). Gene expression score (GES) was defined as the mean Z‐score of the 6 genes specific for recurrent bladder cancer. Results: The intravesical recurrence rate of the high GES group (n = 38) was higher than the low GES group (n = 21). GES was significantly associated with recurrence‐free survival in the validation cohort as well. In prognostic analysis, the European Organization for Research and Treatment of Cancer (EORTC) risk classification was not related to recurrence after TURBT in either univariate or multivariate analysis. On the other hand, the GES we developed was an independent factor for recurrence in NMIBC. Conclusions: A novel gene expression scoring system was shown to predict recurrence in NMIBC patients after TURBT and might be helpful in clinical decision‐making for NMIBC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Darolutamide in Japanese patients with metastatic hormone‐sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.

Author

Uemura, Motohide, Kikukawa, Hiroaki, Hashimoto, Yasuhiro, Uemura, Hiroji, Mizokami, Atsushi, Kato, Masashi, Matsushima, Hisashi, Kosaka, Takeo, Nakamura, Motonobu, Fukasawa, Satoshi, Smith, Matthew R., Tombal, Bertrand, Hussain, Maha, Saad, Fred, Fizazi, Karim, Sternberg, Cora N., Crawford, E. David, Kakiuchi, Haruka, Akiyama, Masanao, and Li, Rui

Subjects
*JAPANESE people, *BODY mass index, *DOCETAXEL, *OVERALL survival, *GLEASON grading system
Abstract

Background: In the global ARASENS study (NCT02799602), darolutamide plus androgen‐deprivation therapy (ADT) and docetaxel significantly reduced risk of death by 32.5% versus placebo plus ADT and docetaxel (hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.57–0.80; p < 0.0001), with a favorable safety profile in patients with metastatic hormone‐sensitive prostate cancer (mHSPC). We investigated outcomes in Japanese participants. Methods: Patients were randomized 1:1 to oral darolutamide 600 mg twice daily or placebo, plus ADT and docetaxel. The primary endpoint was overall survival. Results: The Japanese subgroup comprised 148 patients (darolutamide 63, placebo 85). In the Japanese versus overall population, more patients were aged ≥75 years (darolutamide/placebo 35%/22% vs. 16%/17%) and had body mass index <25 kg/m2 (78%/79% vs. 46%/43%), The ECOG performance status 0 (92%/88% vs. 72%/71%), de novo mHSPC (95%/97% vs. 86%/87%), and Gleason score ≥8 (94%/92% vs. 78%/79%). Median treatment duration was 43.3/15.4 months for darolutamide/placebo. The overall survival HR for darolutamide versus placebo was 0.91 (95% CI 0.50–1.64), despite 85% of patients in the placebo group receiving subsequent life‐prolonging therapy. Darolutamide prolonged time to castration‐resistant prostate cancer (HR 0.31; 95% CI 0.17–0.55). Treatment‐emergent adverse event incidences were generally similar between groups. Adverse events known to be associated with docetaxel (e.g., neutropenia) were more frequent in the Japanese versus overall population. Conclusion: In conclusion, efficacy outcomes showed positive trends for darolutamide plus ADT and docetaxel in Japanese patients with mHSPC, consistent with the overall population, despite higher risk factors. The combination was well tolerated, with no new safety signals in Japanese patients. In Japanese patients with metastatic hormone‐sensitive prostate cancer (mHSPC) who participated in the global phase 3 ARASENS study, darolutamide in combination with androgen‐deprivation therapy (ADT) and docetaxel showed favorable trends in efficacy and tolerability over placebo plus ADT and docetaxel, with no new safety concerns. The outcomes were consistent with the findings in the overall study population and support the use of darolutamide in combination with ADT and docetaxel in Japanese patients with mHSPC as a new standard of care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Prognosis of lower urinary tract symptoms and function after robot‐assisted radical prostatectomy in patients with preoperative low bladder contractility: A prospective, observational study.

Author

Hata, Junya, Matsuoka, Kanako, Akaihata, Hidenori, Yaginuma, Kei, Meguro, Satoru, Hoshi, Seiji, Koguchi, Tomoyuki, Sato, Yuichi, Kataoka, Masao, Ogawa, Soichiro, Uemura, Motohide, and Kojima, Yoshiyuki

Subjects
URINARY organs, RADICAL prostatectomy, BLADDER, SCIENTIFIC observation, PROGNOSIS, URINATION disorders
Abstract

Objectives: To examine the prognosis of lower urinary tract symptoms and function after robot‐assisted radical prostatectomy (RARP) in patients with low preoperative bladder contractility. Methods: A total of 115 patients who underwent RARP were enrolled and divided into two groups by preoperative urodynamic findings: normal (patients with bladder contractility index [BCI] ≥ 100; n = 70) and low contractility (patients with BCI < 100; n = 45) groups. Lower urinary tract symptoms and function parameters were prospectively evaluated at 1, 3, 6, 9, and 12 months after RARP in both groups. Results: International Prostatic Symptom Score voiding scores 1, 3, 6, 9, and 12 months after RARP were significantly higher (p < 0.05), and the maximum flow rate (Qmax) values before and 1, 3, 9, and 12 months after RARP were significantly lower in the low contractility group (p < 0.05). Comparing preoperative and postoperative parameters, IPSS voiding scores in the normal contractility group were significantly improved from 6 months after RARP, whereas those in the low contractility group were almost unchanged. Qmax and the 1‐h pad test in both groups temporarily deteriorated 1 month after RARP, whereas voided volume and postvoiding residual volume significantly decreased from 1 to 12 months after RARP. Conclusions: This observational study showed that patients with low preoperative bladder contractility might have a weak improvement in voiding symptoms and function after RARP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. MP05-07 GDF15 PROPEPTIDE IS A NOVEL BLOOD BIOMARKER FOR CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASIS VIA PROMOTING THE VICIOUS CYCLE

Author

Yamamichi, Gaku, primary, Kato, Taigo, additional, Arakawa, Noriaki, additional, Motoyama, Yuichi, additional, Outani, Hidetatsu, additional, Myoba, Shohei, additional, Ishizuya, Yu, additional, Yamamoto, Yoshiyuki, additional, Hatano, Koji, additional, Kawashima, Atsunari, additional, Uemura, Hiroji, additional, Uemura, Motohide, additional, and Nonomura, Norio, additional

Published
2024
Full Text
View/download PDF

21. Health-Related Quality of Life in Testicular Cancer Survivors in Japan: A Multi-Institutional, Cross-Sectional Study Using the EORTC QLQ-TC26

Author

Yamashita, Shinichi, Kakimoto, Kenichi, Uemura, Motohide, Kishida, Takeshi, Kawai, Koji, Nakamura, Terukazu, Goto, Takayuki, Osawa, Takahiro, Yamada, Shigeyuki, Nishimura, Kazuo, Nonomura, Norio, Nishiyama, Hiroyuki, Shiraishi, Takumi, Ukimura, Osamu, Ogawa, Osamu, Shinohara, Nobuo, Suzukamo, Yoshimi, Ito, Akihiro, and Arai, Yoichi

Published
2021
Full Text
View/download PDF

23. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment

Author

Minami, Keita, Osawa, Takahiro, Kojima, Takahiro, Hara, Tomohiko, Eto, Masatoshi, Takeuchi, Ario, Nakai, Yasutomo, Ueda, Kosuke, Ozawa, Michinobu, Uemura, Motohide, Ohba, Kojiro, Tamura, Keita, Shindo, Tetsuya, Nakagomi, Hiroshi, Takahashi, Atsushi, Anai, Satoshi, Yokomizo, Akira, Morizane, Shuichi, Kimura, Takahiro, Shimazui, Toru, Miyauchi, Yasuyuki, Mitsuzuka, Koji, Hara, Hiroaki, Yoshimura, Koji, Shiina, Hiroaki, Ito, Youichi M, Murai, Sachiyo, Nishiyama, Hiroyuki, Shinohara, Nobuo, and Kitamura, Hiroshi

Published
2023
Full Text
View/download PDF

24. The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study

Author

Kato, Taigo, Nagahara, Akira, Kawamura, Norihiko, Nakata, Wataru, Soda, Tetsuji, Matsuzaki, Kyosuke, Hatano, Koji, Kawashima, Atsunari, Ujike, Takeshi, Imamura, Ryoichi, Nishimura, Kensaku, Takada, Shingo, Tsujihata, Masao, Yamaguchi, Seiji, Takao, Tetsuya, Nishimura, Kazuo, Nonomura, Norio, and Uemura, Motohide

Published
2021
Full Text
View/download PDF

25. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

26. GDF15 PROPEPTIDE IS A NOVEL BLOOD BIOMARKER OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER BY ENHANCING THE VICIOUS CYCLE OF BONE METASTASIS

Author

Yamamichi, Gaku, primary, Kato, Taigo, additional, Motoyama, Yuichi, additional, Outani, Hidetatsu, additional, Ishizuya, Yu, additional, Yamamoto, Yoshiyuki, additional, Hatano, Koji, additional, Kawashima, Atsunari, additional, Nonomura, Norio, additional, Uemura, Motohide, additional, Arakawa, Noriaki, additional, and Myoba, Shohei, additional

Published
2024
Full Text
View/download PDF

28. Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study

Author

Nagahara, Akira, primary, Uemura, Motohide, additional, Sato, Mototaka, additional, Nakata, Wataru, additional, Tsujihata, Masao, additional, Takao, Tetsuya, additional, Matsumura, Soichi, additional, Nishimura, Kensaku, additional, Takada, Shingo, additional, Iwanishi, Toshichika, additional, Kobayashi, Yasuyuki, additional, Ishizuya, Yu, additional, Takada, Tsuyoshi, additional, Okada, Koichi, additional, Inoue, Hitoshi, additional, Kato, Taigo, additional, Hatano, Koji, additional, Kawashima, Atsunari, additional, Ujike, Takeshi, additional, Fujita, Kazutoshi, additional, and Nonomura, Norio, additional

Published
2024
Full Text
View/download PDF

30. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schwentner, Christina A, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Révész, Janos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Scagliotti, Giorgio Vittorio, Bracarda, Sergio, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Erdkamp, Fransiscus L.G., Aarts, Maureen J.B., Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Gajate Borau, Pablo, Grande, Enrique, Delgado Mignorance, Juan Ignacio, Su, Yu-Li, Li, Jian-Ri, Lin, Chien-Liang, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Bondarenko, Igor, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Flaig, Thomas W., Pan, Chong Xian, Schwarz, James K., Cultrera, Jennifer Lyn, Acs, Peter Istvan, Hainsworth, John D., Herms, Benjamin T., Lawler, William Eyre, Lowe, Thomas Eugene, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, and Powles, Thomas

Published
2020
Full Text
View/download PDF

31. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Author

Motzer, Robert J., Robbins, Paul B., Powles, Thomas, Albiges, Laurence, Haanen, John B., Larkin, James, Mu, Xinmeng Jasmine, Ching, Keith A., Uemura, Motohide, Pal, Sumanta K., Alekseev, Boris, Gravis, Gwenaelle, Campbell, Matthew T., Penkov, Konstantin, Lee, Jae Lyun, Hariharan, Subramanian, Wang, Xiao, Zhang, Weidong, Wang, Jing, Chudnovsky, Aleksander, di Pietro, Alessandra, Donahue, Amber C., and Choueiri, Toni K.

Published
2020
Full Text
View/download PDF

32. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data

Author

Hinata, Nobuyuki, Yonese, Junji, Masui, Satoru, Nakai, Yasutomo, Shirotake, Suguru, Tatsugami, Katsunori, Inamoto, Teruo, Nozawa, Masahiro, Ueda, Kosuke, Etsunaga, Toru, Osawa, Takahiro, Uemura, Motohide, Kimura, Go, Numakura, Kazuyuki, Yamana, Kazutoshi, Miyake, Hideaki, Fukasawa, Satoshi, Ochi, Kenya, Kaneko, Hirokazu, and Uemura, Hirotsugu

Published
2020
Full Text
View/download PDF

34. FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab

Author

Kawashima, Atsunari, Yamamoto, Yoshiyuki, Sato, Mototaka, Nakata, Wataru, Kakuta, Yoichi, Ishizuya, Yu, Yamaguchi, Yuichiro, Yamamoto, Akinaru, Yoshida, Takahiro, Takayama, Hitoshi, Takada, Tsuyoshi, Inoue, Hitoshi, Okuda, Yohei, Kato, Taigo, Hatano, Koji, Uemura, Motohide, Nonomura, Norio, and Imamura, Ryoichi

Published
2021
Full Text
View/download PDF

36. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Author

Rini, Brian I, Powles, Thomas, Atkins, Michael B, Escudier, Bernard, McDermott, David F, Suarez, Cristina, Bracarda, Sergio, Stadler, Walter M, Donskov, Frede, Lee, Jae Lyun, Hawkins, Robert, Ravaud, Alain, Alekseev, Boris, Staehler, Michael, Uemura, Motohide, De Giorgi, Ugo, Mellado, Begoña, Porta, Camillo, Melichar, Bohuslav, Gurney, Howard, Bedke, Jens, Choueiri, Toni K, Parnis, Francis, Khaznadar, Tarik, Thobhani, Alpa, Li, Shi, Piault-Louis, Elisabeth, Frantz, Gretchen, Huseni, Mahrukh, Schiff, Christina, Green, Marjorie C, and Motzer, Robert J

Published
2019
Full Text
View/download PDF

39. CHARGE syndrome with both primary and secondary hypogonadism

Author

Yoshida, Yuki, primary, Ogawa, Soichiro, additional, Meguro, Satoru, additional, Onagi, Akifumi, additional, Tanji, Ryo, additional, Matsuoka, Kanako, additional, Hoshi, Seiji, additional, Hata, Junya, additional, Sato, Yuichi, additional, Akaihata, Hidenori, additional, Kataoka, Masao, additional, Uemura, Motohide, additional, and Kojima, Yoshiyuki, additional

Published
2024
Full Text
View/download PDF

40. Downregulation of TCF7 and LEF1 is a key determinant of tumor-infiltrating regulatory T-cell function

Author

Kidani, Yujiro, primary, Kitagawa, Yohko, additional, Hagiwara, Masaki, additional, Kawashima, Atsunari, additional, Kanazawa, Takayuki, additional, Wada, Hisashi, additional, Uemura, Motohide, additional, Nonomura, Norio, additional, Motooka, Daisuke, additional, Nakamura, Shota, additional, Ohkura, Naganari, additional, and Sakaguchi, Shimon, additional

Published
2024
Full Text
View/download PDF

41. Longitudinal changes in factors affecting postoperative patient satisfaction after robot-assisted radical prostatectomy: an assessment using a patient-reported questionnaire

Author

Ogawa, Soichiro, primary, Yaginuma, Kei, additional, Harigane, Yuki, additional, Makabe, Syunta, additional, Imai, Hitomi, additional, Meguro, Satoru, additional, Tanji, Ryo, additional, Onagi, Akifumi, additional, Honda-Takinami, Ruriko, additional, Matsuoka, Kanako, additional, Hoshi, Seiji, additional, Hata, Junya, additional, Sato, Yuichi, additional, Akaihata, Hidenori, additional, Kataoka, Masao, additional, Uemura, Motohide, additional, and Kojima, Yoshiyuki, additional

Published
2023
Full Text
View/download PDF

42. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site

Author

NISHIYAMA, NAOTAKA, primary, KITA, YUKI, additional, ITO, KATSUHIRO, additional, KATO, MINORU, additional, HATAKEYAMA, SHINGO, additional, MATSUSHITA, YUTO, additional, NAITO, SEI, additional, MIYAKE, MAKITO, additional, NAKANISHI, SHOTARO, additional, KATO, YOICHIRO, additional, SHIBUYA, TADAMASA, additional, HAYASHI, TETSUTARO, additional, YASUMOTO, HIROAKI, additional, YOSHIDA, TAKASHI, additional, UEMURA, MOTOHIDE, additional, TAOKA, RIKIYA, additional, NISHIYAMA, HIROYUKI, additional, KOBAYASHI, TAKASHI, additional, and KITAMURA, HIROSHI, additional

Published
2023
Full Text
View/download PDF

43. MO25-4 Clinical outocomes of nivolumab plus ipilimumab in metastatic renal cell carinoma

Author

Kato, Taigo, primary, Fujita, Kazutoshi, additional, Nagahara, Akira, additional, Nakata, Wataru, additional, Matsuzaki, Kyousuke, additional, Hatano, Koji, additional, Kawashima, Atsunari, additional, Takada, Shingo, additional, Nishimura, Kensaku, additional, Tsujihata, Masao, additional, Takao, Tetsuya, additional, Nakai, Yasutomo, additional, Nakayama, Masashi, additional, Nishimura, Kazuo, additional, Uemura, Motohide, additional, Uemura, Hirotsugu, additional, and Nonomura, Norio, additional

Published
2023
Full Text
View/download PDF

47. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma

Author

Taoka, Rikiya, Kobayashi, Takashi, Hidaka, Yu, Abe, Hiroyasu, Ito, Katsuhiro, Kojima, Takahiro, Kato, Minoru, Kanda, Souhei, Hatakeyama, Shingo, Matsui, Yoshiyuki, Matsushita, Yuto, Naito, Sei, Shiga, Masanobu, Miyake, Makito, Muro, Yusuke, Nakanishi, Shotaro, Kato, Yoichiro, Shibuya, Tadamasa, Hayashi, Tetsutaro, Yasumoto, Hiroaki, Yoshida, Takashi, Uemura, Motohide, Kamiyama, Manabu, Morita, Satoshi, Ogawa, Osamu, Nishiyama, Hiroyuki, Kitamura, Hiroshi, and Sugimoto, Mikio

Published
2022
Full Text
View/download PDF

48. Long-term safety and efficacy of enzalutamide for men with castration-resistant prostate cancer: a multicenter, prospective DELC study

Author

Nagahara, Akira, primary, Uemura, Motohide, additional, Sato, Mototaka, additional, Nakata, Wataru, additional, Tsujihata, Masao, additional, Takao, Tetsuya, additional, Matsumura, Soichi, additional, Nishimura, Kensaku, additional, Takada, Shingo, additional, Iwanishi, Toshichika, additional, Kobayashi, Yasuyuki, additional, Ishizuya, Yu, additional, Takada, Tsuyoshi, additional, Okada, Koichi, additional, Inoue, Hitoshi, additional, Kato, Taigo, additional, Hatano, Koji, additional, Kawashima, Atsunari, additional, Ujike, Takeshi, additional, Fujita, Kazutoshi, additional, and Nonomura, Norio, additional

Published
2023
Full Text
View/download PDF

49. PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues

Author

Hoshi, Seiji, primary, Yaginuma, Kei, additional, Meguro, Satoru, additional, Onagi, Akifumi, additional, Matsuoka, Kanako, additional, Hata, Junya, additional, Sato, Yuichi, additional, Akaihata, Hidenori, additional, Kataoka, Masao, additional, Ogawa, Soichiro, additional, Uemura, Motohide, additional, and Kojima, Yoshiyuki, additional

Published
2023
Full Text
View/download PDF

50. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Ng, Siobhan Su Wan, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Chi, Kim Nguyen, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Laestadius, Fredrik, Joly, Florence, Flechon, Aude, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Bamias, Aristotelis, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Peer, Avivit, Sarid, David, Scagliotti, Giorgio Vittorio, Sternberg, Cora N, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Matsubara, Nobuaki, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Jae-Lyun, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Cortés, Leticia Vazquez, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Erdkamp, Fransiscus L G, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Pulido, Enrique Grande, Del Muro, F Xavier García, Mignorance, Juan Ignacio Delgado, Gauna, Daniel Castellano, Rodríguez-Vida, Alejo, Su, Yu-Li, Ou, Yen-Chuan, Lin, Chien-Liang, Su, Wen-Pin, Lin, Chia-Chi, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Coskun, Hasan Senol, Urun, Yuksel, Golovko, Yurii, Bondarenko, Igor, Sinielnikov, Ivan, Powles, Thomas, Crabb, Simon, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Drakaki, Alexandra, Flaig, Thomas, Pan, Chong Xian, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Cultrera, Jennifer, Hainsworth, John, Herms, Benjamin, Lawler, William, Lowe, Thomas, Tagawa, Scott, Aragon-Ching, Jeanny, Vaishampayan, Ulka, Petrylak, Daniel P, Chi, Kim N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Yu, Evan Y, Géczi, Lajos, Hegemann, Miriam, Percent, Ivor J, Tucci, Marcello, Safina, Sufia, del Muro, Xavier Garcia, Rodriguez-Vida, Alejo, Cicin, Irfan, Widau, Ryan C, Liepa, Astra M, Walgren, Richard A, Hamid, Oday, Zimmermann, Annamaria H, and Bell-McGuinn, Katherine M

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results